Skip to main content

Research Repository

Advanced Search

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

Paliouras, AR; Buzzetti, M; Shi, L; Donaldson, IJ; Magee, P; Sahoo, S; Leong, H‐S; Fassan, M; Carter, M; Di Leva, G; Krebs, MG; Blackhall, F; Lovly, CM; Garofalo, M

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition Thumbnail


Authors

AR Paliouras

M Buzzetti

L Shi

IJ Donaldson

P Magee

S Sahoo

H‐S Leong

M Fassan

M Carter

G Di Leva

MG Krebs

F Blackhall

CM Lovly

M Garofalo



Abstract

A subset of lung adenocarcinomas is driven by the EML4‐ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on‐target mutations or parallel pathway alterations is a major clinical challenge. Exploring these mechanisms of resistance, we found that EML4‐ALK cells parental or resistant to crizotinib, ceritinib or alectinib are remarkably sensitive to inhibition of CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib. These compounds robustly induce apoptosis through transcriptional inhibition and downregulation of anti‐apoptotic genes. Importantly, alvocidib reduced tumour progression in xenograft mouse models. In summary, our study takes advantage of the transcriptional addiction hypothesis to propose a new treatment strategy for a subset of patients with acquired resistance to first‐, second‐ and third‐generation ALK inhibitors.

Citation

Paliouras, A., Buzzetti, M., Shi, L., Donaldson, I., Magee, P., Sahoo, S., …Garofalo, M. (2020). Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition. EMBO Molecular Medicine, 12(7), e11099. https://doi.org/10.15252/emmm.201911099

Journal Article Type Article
Acceptance Date May 21, 2020
Online Publication Date Jun 17, 2020
Publication Date Jul 7, 2020
Deposit Date Jun 29, 2020
Publicly Available Date Jun 29, 2020
Journal EMBO Molecular Medicine
Print ISSN 1757-4676
Electronic ISSN 1757-4684
Publisher Wiley
Volume 12
Issue 7
Pages e11099
DOI https://doi.org/10.15252/emmm.201911099
Keywords Molecular Medicine
Publisher URL https://doi.org/10.15252/emmm.201911099
Related Public URLs http://embomolmed.embopress.org/
Additional Information Additional Information : ** Article version: VoR ** From Crossref via Jisc Publications Router ** Licence for VoR version of this article starting on 17-06-2020: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: pissn 1757-4676; eissn 1757-4684 **History: issued 17-06-2020; published_online 17-06-2020

Files






Downloadable Citations